CHRS
Coherus BioSciences Inc
Price:  
1.11 
USD
Volume:  
1,686,889.00
United States | Biotechnology
Valuation
Overview
Financials
Forecast
Compare
Historical Price
SolvencyDividends
Transactions
People

CHRS WACC - Weighted Average Cost of Capital

The WACC of Coherus BioSciences Inc (CHRS) is 8.7%.

The Cost of Equity of Coherus BioSciences Inc (CHRS) is 13.50%.
The Cost of Debt of Coherus BioSciences Inc (CHRS) is 7.35%.

Range Selected
Cost of equity 11.50% - 15.50% 13.50%
Tax rate 0.10% - 1.10% 0.60%
Cost of debt 7.00% - 7.70% 7.35%
WACC 8.0% - 9.4% 8.7%
WACC

CHRS WACC calculation

Category Low High
Long-term bond rate 3.9% 4.4%
Equity market risk premium 4.6% 5.6%
Adjusted beta 1.67 1.91
Additional risk adjustments 0.0% 0.5%
Cost of equity 11.50% 15.50%
Tax rate 0.10% 1.10%
Debt/Equity ratio 3.49 3.49
Cost of debt 7.00% 7.70%
After-tax WACC 8.0% 9.4%
Selected WACC 8.7%